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osting by EAbstract Thyroid cancer is the most prevalent endocrine malignancy. The preoperative diagnosis
of differentiated thyroid cancer (DTC) that relies solely on ﬁne-needle aspiration (FNAC) biopsy,
sometimes possesses conﬂicting results. New molecular markers for thyroid cancer have been inves-
tigated with most of them based on the detection in thyroid nodules or tumor tissue specimens.
Recently, it was possible to detect thyroid cancer cells in the circulation by measuring the mRNA
of thyroid speciﬁc genes. Among these, thyroglobulin and more recently thyroid stimulating hor-
mone receptor mRNAs, TSHR/Tg-mRNAs in peripheral blood might serve as cancer-speciﬁc
markers. These have become promising new circulating markers for thyroid cancer.
The purpose of this study is to assess TSHR/Tg-mRNAs as diagnostic molecular markers for thy-
roid cancer and if they can be used preoperatively in synergy with FNAC.
This study was performed on 60 subjects; 20 healthy volunteers and 40 patients; including 16
patients with benign thyroid diseases, 24 patients with thyroid cancer; 18 patients with newly diag-
nosed (DTC) and 6 patients with recurrent thyroid cancer. Diagnosis of cancer was based on FNACr City El Waha, Building 1,
m (S.H.A. Agwa).
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202 S.H. Teama et al.and histopathology of surgical specimens. All subjects had TSHR/Tg-mRNAs in peripheral blood
measured by reverse transcriptase (RT)-PCR.
Based on cytology/pathology; 18 patients had newly diagnosed DTC and 11 had benign thyroid
disease. Preoperative FNAC was performed on 29 of 40 patients; FNAC was diagnostic in 11/18 of
malignant lesions (61.1%), in 8/11 of benign lesions (72.7%), while 10/29 (34.5%) were indetermi-
nate. TSHR/Tg-mRNAs correctly diagnosed DTC in 20/24 and 19/24 (sensitivity 83.3% and
79.1%) and benign disease in 14/16 and 13/16 (speciﬁcity 87.5% and 81.3%), respectively. With
indeterminate FNA, TSHR/Tg-mRNAs correctly diagnosed DTC (follicular type) in 5/7 and
benign disease in 2/3 (combined sensitivity 71.4%; speciﬁcity 66.7%). There was high concordance
between RT-PCR results for TSHR-mRNA and Tg-mRNA. Of the controls 19/20 (95%) and 16/20
(80%) were negative for both TSHR- and Tg-mRNAs.
With the use of a carefully selected primer pair and qualitative RT-PCR; our results indicate that
TSHR/Tg-mRNAs in peripheral blood are both equally sensitive and speciﬁc markers for detection
of thyroid cancer cells. Combining TSHR/Tg-mRNAs and FNAC and ultrasound enhances the pre-
operative detection of cancer in patientswith thyroid nodules, reducing unnecessary surgeries and cor-
rectly classiﬁed most follicular cancers and could have spared surgery in patients with benign disease.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Human thyroid tumors originate from epithelial follicular cells
or from parafollicular C-cells. Follicular cell-derived tumors
range from benign adenomas to differentiated (follicular and
papillary) and undifferentiated (anaplastic) carcinomas [1].
Well-differentiated thyroid carcinoma (DTC) is the most
common endocrine malignancy, with an annual incidence of
0.5–10 cases per 100,000 individuals. Its management includes
thyroidectomy and I 131 ablation therapies. Differentiated
thyroid carcinoma (DTC) has an overall favorable prognosis,
with a 10-year survival of 90–95% [2].
Twomainareas of thyroid cancermanagement that couldben-
eﬁt from improvements are the preoperative diagnosis of thyroid
cancer when a biopsy suggests intermediate features, and a more
reliable diagnosis of postoperative thyroid cancer recurrence.
Despite the increasing standards of imaging techniques like
ultrasound, ﬁne-needle aspiration (FNAC) remains the proce-
dure of choice in patients presenting with thyroid enlargement.
FNAC is reliable, safe and accurate method as a ﬁrst line of
evaluation in thyroid gland nodules before surgery. Thyroid
nodules are extremely common with prevalence rates
approaching 50–60% of adults under 60 years of age. Gener-
ally, most (90%) thyroid nodules are benign and can be classi-
ﬁed as adenomas, colloid nodules, cysts, infectious nodules,
lymphocytic or granulomatous nodules, hyperplastic nodules,
thyroiditis, and congenital abnormalities. Because only
approximately 5% of thyroid nodules are malignant, accurate
preoperative characterization of thyroid nodules is critical in
selecting patients appropriate for surgical thyroidectomy [2].
FNAC is more speciﬁc than sensitive in detecting thyroid
gland malignancy and, therefore it is used as a reliable diag-
nostic test. However, the instance of inadequate sampling of
the lesion and overlapping cytological features of benign and
malignant thyroid neoplasms are inherent limitations of this
technique, often requiring multiple biopsies or unnecessary
surgeries. For papillary thyroid cancer, FNAB has proven
exceedingly accurate. However, 15–30% of FNAB specimens
have intermediate cytology features often described as hyper-
cellular follicular lesions of follicular neoplasm that lead to
surgery for deﬁnitive diagnosis. Some of these lesions will befollicular thyroid carcinomas or follicular variants of papillary
thyroid cancer, but most are benign on ﬁnal pathology. The
problem is that the distinction by FNAC between benign
and malignant follicular neoplasms remains difﬁcult, as the
crucial criterion for FTC vs. adenoma (FA) is capsular inva-
sion, which cannot be determined by cytology. In addition,
the distinction between FA and Follicular variant of PTC
(FVPTC) is also difﬁcult, because the crucial criterion here is
the aspect of the nuclei. The implication is that 70–80% of
the patients with suspicious results from FNA, who undergo
thyroid surgery have a benign tumor [3,4].
Based on several promising studies, molecular markers can
potentially improve the diagnostic accuracy of FNAC. Molec-
ular markers that alone or in combination with FNAC could
detect cancer for preoperative evaluation is highly desirable
and could save a number of unnecessary surgeries [5–7].
Thyroid-stimulating hormone (TSH; thyrotropin) and TSH
receptor (TSHR) are key proteins in the control of thyroid
function. The human TSHR gene is located on chromosome
14q31and is encoded by 10 exons of which the last exon en-
codes the entire transmembrane and intracellular region.
TSHR is the receptor for thyrotropin; a member of the glyco-
protein hormone family. TSH is released by the anterior pitu-
itary gland and is the main regulator of thyroid gland growth
and development. Binding of TSH to TSHR stimulates thy-
roid-epithelial cell proliferation, and regulates the expression
of differentiation markers such as thyroglobulin, thyroperoxi-
dase and the sodium iodide symporter (NIS), necessary for the
synthesis of thyroid hormones [8]. Thyroglobulin production
by both normal and neoplastic thyroid tissues depends on
the presence of functional TSHR and is inﬂuenced by TSH lev-
els. The expression of TSHR in thyroid neoplasms has been
well documented as both thyroid/thyroid cancer cells express
functional TSHR [9,10].
Thyroglobulin (Tg) is a 660,000-Kd glycoprotein, Tg gene
mapped to human chromosome 8q24.2–8q24.3 covers at least
300 kb of genomic DNA and contains 8.5 kb coding sequence
divided over 48 exons separated by introns varying in size up
to 64 kb. Tg is considered a thyroid-epithelial cell-speciﬁc
product. Its serum levels represent a widely accepted marker
for monitoring patients with DTC after thyroidectomy and
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lation with the volume of differentiated thyroid tissue present.
However, the various sTg assays are plagued by a number of
methodological problems, occasionally limiting the clinical va-
lue of routine sTg measurements [11,12].
Molecular markers have been explored as alternative meth-
od for the detection of thyroid cancer with variable success and
suffer from the lack of speciﬁcity. The variable results in these
studies may relate to the differences in methods used including
RNA isolation, use of different primers, and the normalization
process [6].
Our objective was to assess these two markers TSHR/Tg-
mRNAs as diagnostic markers for thyroid cancer to determine
its sensitivity and speciﬁcity and if they can be used in synergy
with current diagnostic modalities; ﬁne needle aspiration and
ultrasound for preoperative diagnosis (Fig. 1).
2. Subjects and methods
2.1. Subjects
The subjects were conducted from National Cancer Institute,
Cairo University and Endocrine Department of Ain-Shams
University Hospitals during period from December 2009 to
June 2010. Follow-up: postoperative pathological diagnosisFigure 1 Algorithm for the evaluation of thyroid disorders. TSH= t
HB [13].was used to categorize the patients into benign and malignant,
a total of 60 subjects including 3 groups.
2.1.1. Control group
Group A: Included 20 apparently healthy people of matched
age and sex as the patient groups without history of diseases.
2.1.2. Patient groups
Group B: Comprised 16 patients with benign thyroid diseases.
Among those patients; two patients had thyroiditis, 9 had thy-
roid nodules/multinodular goiter, and ﬁve had Grave’s disease
(diffuse toxic goiter).
Group C: Comprised 24 patients with differentiated thyroid
cancer (DTC); 18 patients newly diagnosed cases differentiated
thyroid carcinoma and 6 patients with recurrent or residual
DTC on T4 replacement therapy.
All subjects were subjected to history taking, clinical exam-
ination, laboratory investigations including: CBC, liver func-
tion test, kidney function test, prothrombin time, thyroid
proﬁle, thyroid antibodies and thyroid U/S, while U/S guided
FNAC was done only for 29 patients who were presenting with
nodular thyroid disease out of forty patients (in patients with
MNG; FNAC was done on the predominant cold nodule
according to isotope scan ﬁnding). The remaining 11 patients
did not require FNAC as ﬁve patients were proven clinicallyhyroid-stimulating hormone; FNA= ﬁne-needle aspiration Burch
Table 1 Setting of PCR primers 7.
Sequence of primers Ampliﬁed product
TSHR F 50-GCTTTTCAGGGACTATGCAATGAA-3’
R 30-AGAGTTTGGTCAC-AGTGACGGGAA-5’ 212
Tg F 50-AGGGAAACGGCCTTTCTGAA-3’
R 30-CTTTAGCAGCAGAAGAGGTG-5’ 407
GAPDH F 50-CGTCTTCACCACCATGGAGA 3’
R 50-CGGCCATCACGCCACAGTTT 3’ 300
204 S.H. Teama et al.and by lab results to have Grave’s disease, while the remaining
6 patients had recurrent thyroid cancer. In selected cases thy-
roid isotope scans, CT scan were required and were done. Data
were included in chart review. Written informed consent was
obtained before enrollment into the study.
Patients had FNA biopsy performed and blood samples
drawn before surgery. Postoperative pathological diagnosis
was used to categorize the patients into benign and malignant.
FNA sample adequacy included sufﬁcient number of cells,
abundant colloid, and the presence of at least six groups of be-
nign follicular cells composed of at least 10 cells each. The re-
sults were compared with ﬁnal postoperative pathological
diagnosis. Indeterminate FNA included the following cytolog-
ical categories: hypercellular follicular nodule (oxyphilic or
non oxyphilic), atypical epithelial cells and hemorrhagic cyst
contents with few follicular cells.
2.2. Methods
2.2.1. Blood samples
Ten milliliters was sampled from the peripheral veins from
each patient and from controls for separation of mononuclear
cells.
2.2.1.1. Isolation of peripheral blood mononuclear cells. Periph-
eral blood mononuclear cells (PBMCs) were isolated from
blood by density gradient centrifugation using Ficoll-hypaque
1077 (Sigma, USA) at 1200g for 30 min at 4 C. The interface
cells were removed, washed twice with 25 ml of sterile PBS (pH
7.3), pelleted, and resuspended in 1 ml of PBS. The cells were
pelleted again at 1200g for 2 min. The cell pellets were kept at
80 C until RNA extraction.
2.2.1.2. Extraction of total RNA from nuclear cells. Total RNA
of nuclear cells separated from whole blood was extracted
using RNA extraction kit (Qiagen). The isolated RNA was
resuspended in RNAase-free water and stored at 80 C untilTable 2 Patients characteristic in various diagnostic groups.
Normal Benign
No. of patients 20 16
Age 48.8 ± 11.33 54.8 ± 10.1
Sex
Male 6 (30%) 7 (43.8%)
Female 14 (70%) 9 (56.2%)
Surgical conﬁrmation 11
FNAC 8/11
Cytology/pathology nodules/MNG, 2 thyroditisassay. The RNA concentration was assessed by absorbance
reading at 260 nm with UV spectrophotometry (Du series
650, Beckman Inc., USA).
2.2.1.3. Reversetranscription (complementary cDNA synthesis).
Reverse transcription reaction was carried out in 20 ll reaction
mixture by using ﬁrst strand cDNA synthesis kit (Promega;
USA) according to the manufactures instructions.
2.2.1.4. PCR ampliﬁcation of TSHR and Tg. PCR was per-
formed using the selected primer pairs. Five microliters of
ﬁrst-strand cDNA was used as a template for the PCR reac-
tion. Each reaction mixture consisted of 0.5 mM of each pri-
mer, 10· Taq Buffer, 2.5 mM dNTP mix, 0.5 U of Taq
polymerase and nuclease-free water to a ﬁnal volume of
50 ll. Thermocycling in either an MJ Research PTC 200 (MJ
Research, Inc., Boston, MA) or Perkin-Elmer 9600 (Perkin-El-
mer, Cambridge, UK) consisted of 38 cycles of denaturation
(94 C, 1 min; (ﬁrst cycle for 2 min), annealing (62 C, 1 min)
and extension (72 C, 1 min) (10 min for the last cycle). PCR
ampliﬁcation of GAPDH to assess the cDNA integrity is
shown in Table 1.
2.2.1.5. Analysis of ampliﬁed thyroglobulin/TSHR cDNA. Ten
microliters of PCR product was mixed with 2 ll 6· and the
ampliﬁed PCR products were analyzed by agarose gel electro-
phoresis, stained with ethidium bromide (Sigma), and visual-
ized with an UV transilluminator (Bio-Rad).
2.3. Statistical analysis
The results were analyzed using the Statistical Package of So-
cial Sciences (SPSS) computer software program, version 16.0
(Chicago, IL, USA). Quantitative data were presented as
mean ± SD for normally distributed data. Qualitative data
were presented in the form of frequencies and percentages.
For normally distributed parameters, differences amongNewly diagnosed DTC Recurrent thyroid cance
18 6 (PTC)
60.2 ± 7.3 63.5 ± 6
6 (33.3%) 1 (16.7%)
12 (66.7%) 5 (83.3%)
18
11/18
and 3FA 12PTC and 6Fr
Figure 2 Categorization of patients according to FNAC and surgical results.
Figure 3 Electrophoretic separation of PCR ampliﬁed product.
Detection of gene transcripts in blood specimens from thyroid
cancer patients. Lane 1: DNA molecular size marker. Lanes 2 ,4,
5, 7: negative cases. Lanes 3, 6, 8: cases showing TSHR/Tg positive
gene transcript. Lane 9: negative control.
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For qualitative data, differences among groups were tested
using Pearson’s chi-square test (v2) and Fisher’s exact test.
Data were analyzed for diagnostic sensitivity and speciﬁcity
of TSHR-mRNA and Tg-mRNA for detection of thyroid can-
cer sensitivity, speciﬁcity and accuracy was calculated.
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Patients Characteristic
A total of 40 patients were enrolled in the study (27 female
67.5%; 13 male 32.5%). Demographic data represented in
Table 2 in addition to 20 healthy controls.Table 3 TSHR/Tg-mRNAs positivity in healthy individuals and in
n TSHR-mRNA
Healthy volunteers 20 1 (5%)
Benign thyroid disease 16 2 (12.5%)
Thyroid cancer patients 24 20 (83.3%)
v2 36.893
P-value <0.01 HS
a Healthy and benign.
b Benign and malignant.
c Healthy and malignant.Neither age nor sex was correlated with the presence of
TSHR/Tg-mRNAs expression ( P> 0.05). Twenty-nine pa-
tients had FNA biopsy performed before surgery. Postopera-
tive pathological diagnosis was used to categorize the
patients into benign and malignant. Diagnosis of Grave’s dis-
ease as well as of healthy individuals was based on clinical
assessment and appropriate ultrasound examination; thyroid
proﬁle (thyroid-stimulating hormone (TSH), total thyroxin
(T4) and triiodothyronine (T3). In a hyperthyroid patient with
nodular thyroid disease the risk of malignancy is low. FNAC
does not need to be performed routinely in these patients un-
less clinical features suggestive of malignancy are present.
These features include a history of neck irradiation, rapid
growth, family history, hard consistency, local lymphadenopa-
thy and recurrent laryngeal nerve palsy in the absence of pre-
vious surgery [14,15]. Tests for serum thyroid autoantibodies
are done as these may indicate autoimmune thyroid disease.
Categorization of patients according to FNAC and surgical
results is demonstrated in Fig. 2.
3.2. Interpretation results
After optimization of conditions for reverse transcription and
polymerase chain reaction and according to the design of pri-
mer pairs we were able to detect the PCR products of 212; 407
base pairs were ampliﬁed from TSHR/Tg cDNA, respectively;
while GAPDH band ampliﬁcation was visualized correspond-
ing to 300 bp. No transcripts were identiﬁed in the water con-
trol or in the RT-negative control. The sizes of PCR products
were estimated by comparison with DNA molecular mass
markers (Bio-Rad; EZ Load) Fig. 3.patients with benign thyroid disease and thyroid cancer.
Tg-mRNA P1 P2 P3
4 (20%) >0.05a <0.01b <0.01c
3 (18.7%)
19 (79.1%)
30.343
<0.01 HS
Table 4 Statistical analysis of TSHR/Tg-mRNAs’ results.
Disease Positive Disease Negative
Test (TSHR-mNA) n= 40
Positive 20 TP 2 FP
Negative 4 FN 14 TN
Test (Tg-mNA) n= 40
Positive 19 TP 3 FP
Negative 5 FN 13 TN
Sensitivity = TP/TP+FN · 100, speciﬁcity = TN/TN+FP · 100,
PPV= TP /TP + FP · 100, NPV= TN/TN+ FN · 100, accu-
racy = TP+ TN/total no. · 100; TP = true positive, TN= true
negative, FP = false positive, FN= false negative, PPV= positive
predictive value, NPV= negative predictive value.
Table 5 Diagnostic performance of TSHR, Tg and FNA
result in patients with benign thyroid disease and thyroid
cancer.
Variables TSHR-mRNA (%) Tg-mRNA (%)
Sensitivity 83.3 79.1
Speciﬁcity 87.5 81.3
PPV 90.9 86.4
NPV 77.8 72.2
Accuracy 85 80
206 S.H. Teama et al.3.3. FNAC result compared with histological diagnosis
Based on cytology/pathology; 18 had surgically conﬁrmed
DTC. 11 patients had benign conditions; FNA result of malig-
nant conditions: 11/18 (61.1%) were FNAC results of newly
diagnosed DTC (papillary carcinoma), FNA result of benign
conditions: 8 were FNAC results of benign condition 6 pa-
tients diagnosed nodule/MNG, and 2 patients with Hashimoto
thyroiditis and 3/11 (27.3%) patients had sufﬁcient specimen
but inconclusive results; surgically conﬁrmed follicular ade-
noma. FNAC of indeterminate result with 6 were surgically
proven to be follicular carcinoma while 3 were surgically pro-
ven to be benign follicular adenoma and 1 papillary thyroid
carcinoma.
3.4. Evaluation of reverse transcriptase-PCR (RT-PCR) results
in controls and patients
Forty patients (24 DTC; 16 benign) were enrolled at initial
diagnosis and 20 control patients without clinical signs or a
history of thyroid disease.Table 6 Sensitivity and speciﬁcity of combined TSHR/Tg-mRNA
thyroid cancer.
Thyroid cancer
Positive Sensitivi
FNA 11/18 61.1
TSHR/Tg-mRNA 21/24a 87.5
FNA 20/24b 83.3
a TSHR-mRNA.
b Tg-mRNA.3.4.1. TSHR/Tg-mRNAs in normal control and benign thyroid
disease
Of the controls 19/20 (95%) and 16/20 (80%) were negative for
both TSHR- and Tg-mRNAs. Of the patients with benign thy-
roid disease, 14/16 (87.5%) and 13/16 (81.3%) were negative
for both TSHR- and Tg-mRNA. False positive for TSHR/
Tg included two patients with follicular adenoma (Tables 3
and 4).
3.4.2. TSHR/Tg-mRNAs in thyroid cancer
Twenty four patients were evaluated (six patients had recur-
rent or residual malignant disease at the time of enrollment
and 18 were recently diagnosed with differentiated thyroid
cancer (12 papillary, 6 follicular cancers). There were 20/24,
19/24 patients (83.3%, 79.1%) with DTC who were positive
for TSHR/Tg-mRNAs in the peripheral blood. (All six pa-
tients with recurrent disease were positive by RT-PCR.) (Ta-
bles 3 and 4).
There was high concordance between RT-PCR results for
TSHR-mRNA and for Tg-mRNA, also combined model for
both markers with FNAC showed improved sensitivity and
speciﬁcity (Tables 5 and 6).
4. Discussion
Molecular detection of tissue-speciﬁc gene expression in
peripheral blood is a new diagnostic approach and has been
described as a tumor marker in different solid tumors. The
RT-PCR is a highly sensitive technique for the detection of tis-
sue-speciﬁc mRNA transcripts. This method has been tested
with the ampliﬁcation of cancer-speciﬁc mRNA from periphe-
ral blood to detect micrometastases in cases of prostate cancer
and neuroblastoma [6]. Many studies explored blood-borne
thyroglobulin/TSHR-mRNAs as a potential tumor marker in
thyroid cancer [16,17]. A reliable and satisfying method that
is able to differentiate preoperative malignant potential in pa-
tients presenting with thyroid nodules has not yet been
proposed.
Ditkoff et al. [18] reported, for the ﬁrst time, a method for
detecting Tg-mRNA in peripheral blood of patients with well-
differentiated thyroid tumors. Since the authors were not able
to document Tg expression either in controls or in patients
with benign thyroid disease, Tg-mRNA appeared to be a spe-
ciﬁc tumor marker. In contrast, different studies revealed that
Tg transcripts could be found in blood from healthy control
[19–21] in a variety of human cell lines and in different human
tissues and organs [22]. This could be attributed to illegitimate
transcription of Tg-mRNA [23–26]; any gene is expressed in
any cell at very low, but detectable levels, or could mean thats and FNA result in patients with benign thyroid disease and
Benign conditions
ty (%) Negative Speciﬁcity (%)
8/11 72.7
15/16a 93.7
14/16b 87.5
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taking place even in normal thyroids.
Thyroid carcinomas are known to contain functional
TSHR [27]; this target has not been exploited for detection
of circulating cancer cells, perhaps due to previous reports
showing the presence of TSHR-mRNA transcripts in periphe-
ral blood mononuclear cells [28] and other extrathyroidal tis-
sues [29]. The ﬁnding of these transcripts in extrathyroidal
tissues can be explained by TSHR splice variants [30,31]. Such
inconsistent results suggested that different RNA extraction
methods, RT-PCR conditions, and primers could also interfere
with the ﬁnal results. It is possible that with certain primer
pairs ampliﬁcation of pseudogenes can give rise to false-posi-
tive results. Thus, selection of primers speciﬁc to thyroid cells
is of paramount importance in the assay.
In the present study based on cytology/pathology, 18 pa-
tients had newly diagnosed DTC and 11 had benign thyroid
disease. There was high concordance between RT-PCR results
for TSHR-mRNA and for Tg-mRNA. TSHR/Tg-mRNAs
correctly diagnosed DTC in 20/24, 19/24 patients (83.3%,
79.1%) and 11/18 (61.1%) of newly diagnosed cases and be-
nign disease in 14/16, 13/16 (87.5%, 81.3%), respectively. In
this study, 34.4% of FNA biopsies were called indeterminate
among which 6 were surgically proved to be follicular carci-
noma while 3 were surgically proved to be benign follicular
adenoma and 1 papillary thyroid carcinoma. These indetermi-
nate thyroid nodules seem to be one of the most frustrating
and challenging areas for the endocrinologists and endocrine
surgeons. Most studies are focused on FNAC material to iden-
tify molecular markers or a combination of markers as a
means of improving the accuracy of diagnosis made by FNAC
[6].
The ﬁnding of circulating thyroid cells in patients with fol-
licular adenoma favors that some follicular adenomas may be
present at premalignant stages of follicular carcinomas. The
differentiation between follicular adenoma and follicular carci-
noma is, at present, only possible after surgical resection and
formal histological examination. To date, there are no known
markers that can distinguish follicular adenomas from cancer
with certainty because, like follicular cancer, a signiﬁcant num-
ber of follicular adenomas harbor Ras mutations and show
galectin-3 immunoassaying. Therefore, the ﬁnding of circulat-
ing thyroid cells in a patient with follicular adenoma is not
unparalleled and favors the notion that some follicular adeno-
mas may represent a premalignant stage of follicular
carcinomas.
Feilchenfeldt et al. [32] observed a signiﬁcant increase in
galectin-3 on mRNA and protein levels in papillary thyroid
cancers. No follicular thyroid cancer was positive with regard
to galectin-3 mRNA levels. Hence, galectin-3 expression or
immunoreactivity does not appear to be useful tool in distin-
guishing adenomas from follicular cancers in cytological or
histological specimens. However, it remains to be seen whether
galectin-3 will prove useful in detecting the follicular variant of
papillary cancers or a multifocal spread on histological
material.
Jakubiak-Wielganowicz et al. [33] reported that although
galectin-3 was not proven to be highly speciﬁc or sensitive
for given type of thyroid tumor, it seems to be a valuable tool
helping in diagnosis of difﬁcult thyroid tumors, but can not be
used as a speciﬁc marker. Galectin-3 may be helpful in preop-
erative diagnosis of tumors diagnosed cytologically as ‘‘follic-ular tumor, suspected for neoplasm’’. As galectin-3 may be
present in some adenomas, it does not seem to be a tool in dif-
ferentiating between follicular variant of papillary carcinoma
and follicular adenoma.
It is recognized that FNAC cytology has a high sensitivity for
PTC. On the other hand, FNAC cannot differentiate between
FC and FA [4,34]. In this study TSHR/Tg-mRNAs correctly
differentiated between follicular carcinoma in 5/7 of thyroid
cancer patients and follicular adenoma in 2/3 benign disease pa-
tients (sensitivity 71.4%; speciﬁcity 66.7%), similar results were
found by Wagner et al. [7]. Our results suggest that circulating
preoperative TSHR/Tg-mRNA acts as an adjunctive test to en-
hance the diagnostic accuracy of FNAC and indicate a high po-
tential of TSHR/Tg-mRNA to differentiate FC from FA and
await conﬁrmation in future studies with a larger number of pa-
tients. This is in concordance with Wagner et al. [7] who docu-
mented in his study that preoperative TSHR/Tg classiﬁed
78% (14/18) of nodules with indeterminate FNA accurately.
Yet contrary to our results Torosian et al. [20] found that
Tg and TSHR-mRNA signals were detected equally in all sub-
jects (patients with DTC with and without evidence of disease
and in normal subjects).
The variability in Tg-mRNA results in various studies may
be explained by the alternative splicing of Tg-mRNA in thy-
roid cells, as at least 16 alternative splicing sites have been re-
ported. Moreover, thyroid carcinomas may produce Tg
molecules of altered structure, a phenomenon that may be
associated with difﬁculties in the detection of these forms by
various immunoassays [10]. Another explanation a phenome-
non related to the speciﬁcity of the oligonucleotide primers
used in various RT-PCR protocols and to the PCR conditions,
such as the number of ampliﬁcation cycles, which signiﬁcantly
alter the sensitivity of the assays [23,24].
Previous report demonstrated that RT-PCR has been dem-
onstrated to be more sensitive than sTg assays, especially dur-
ing T4 therapy or in the presence of anti-Tg antibodies.
However, the existence of several alternative splicings of the
Tg-mRNA has raised the question of the frequency of these
variants in thyroid tissues in diseased and normal subjects.
In fact, the transcription pattern of Tg-mRNA is heteroge-
neous in thyroid cancer tissues, as well as in normal thyroid tis-
sues, and no speciﬁc pattern has been found in differentiated
thyroid carcinoma.
A Bojunga et al. [25] clearly documented the fact that a
change in the number of PCR cycles was sufﬁcient to alter
the percentage of positive cases obtained in different groups
of individuals with benign and malignant thyroid diseases.
A major ﬁnding in the present study is that the presence of
TSHR/Tg-mRNAs signals in blood is speciﬁc for patients with
thyroid cancer, being undetectable in the vast majority of
healthy volunteers and patients with benign thyroid diseases.
The high speciﬁcity of TSHR-mRNA and Tg-mRNA for thy-
roid cancer because carefully selected primers are used in the
assay.
A model for combined sensitivity and speciﬁcity of TSHR/
Tg-mRNAs and FNAC results in patients with benign thyroid
disease and thyroid cancer revealed 21/24 (87.5%), 20/24
(83.3%) in patients with thyroid cancer and 15/16 (93.7%),
14/16 (87.5%) in patients with benign thyroid disease compared
to (61.1%) in thyroid cancer and (72.7%) in benign thyroid dis-
ease when using FNAC alone, this algorithm can contribute to a
more accurate diagnosis prior to operation especially of indeter-
208 S.H. Teama et al.minate thyroid lesions or follicular neoplasms than other cur-
rently available strategy, nevertheless this algorithm requires
prospective validation and comparison with other suggested
models combiningmolecularmarkers withUS features .Finally,
it is worth noting that TSHR/Tg-mRNAs correctly diagnosed
all recurrent thyroid cancer cases, which implies the utility of
TSHR/Tg-mRNAs in long-term monitoring and detection of
cancer recurrence and residual disease which is concordant with
earlier reports of correlation of elevated levels with the presence
of residual/ metastatic disease and that it could postoperatively
predict recurrent cancer [6,10].
A standardization of cDNA preparation, gene-speciﬁc pri-
mer pairs, optimal RT-PCR conditions and the determination
of possible threshold caused by cells of non-thyroid origin is
mandatory to obtain reliable and comparable results. In view
of our data obtained for sensitivity and speciﬁcity, we believe
that a clinically useful assay will require further assay reﬁne-
ment, e.g. quantitative assay to permit the distinction of weakly
and more strongly positive RT-PCR results. A number of ques-
tions remain to be answered and further studies are necessary.
5. Conclusion
In summary, the presence of either TSHR-mRNA or Tg-
mRNA in peripheral blood is speciﬁc for the presence of circu-
lating thyroid cells; and represent speciﬁc and sensitive mark-
ers for thyroid cancer and expression of this marker shows
promise for detecting FC, which is often missed by FNAC.
Overall, the management of cancer in general and thyroid can-
cer in particular is moving away from reliance on a single test
that replaces others. The ultimate usefulness of molecular
markers as TSHR/Tg-mRNAs may reside in being part of a
multimodality panel of clinical tests. An envisioned new algo-
rithm may combine the best of all management criteria clinical
assessment, radiologic and histologic information, and the bio-
logic implications of a molecular marker.
5.1. Future perspectives
The use of molecular diagnostic techniques, such as RT-PCR,
which enable the speciﬁc ampliﬁcation of small numbers of
mRNA molecules, has led to the development of several meth-
ods for the speciﬁc ampliﬁcation of small foci of malignant tis-
sue, either primary or metastatic. PCR-based techniques may
improve the preoperative diagnosis of patients with thyroid
malignancies and therefore help to avoid unnecessary radical
procedures. Quantitative TSHR-mRNA assay is helpful in
the preoperative diagnosis of thyroid nodules, particularly in
the subgroup of patients with indeterminate FNA. The imme-
diate postsurgical levels can serve as a sensitive marker for
detecting residual/metastatic disease. Furthermore, it detects
recurrent cancer with high sensitivity and can be valuable as
an alternative to serum Tg measurement in patients who har-
bor Tg antibodies. Future studies are required to establish its
role in long-term monitoring.
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